GSK, Pfizer sue Hikma over clotting-drug patent; Valeant to relocate HQ to Quebec;

@FiercePharma: One big hit to script numbers: Seniors avoiding the doc, holding off on refills for cost reasons--BloombergMore | Follow @FiercePharma

> GlaxoSmithKline ($GSK) and Pfizer ($PFE) sued Hikma Pharmaceuticals alleging patent infringement as the Jordanian drugmaker prepares to launch a version of the blood-clotting drug argatroban. News

> Valeant Pharmaceuticals ($VRX) said it would relocate its global headquarters to Quebec from Montreal and will set up a new R&D center for dermatology nearby. Report

> The Texas Department of Criminal Justice won't disclose the size of its lethal-injection drug stocks, saying that the information would create risks to its suppliers. More

> Watson Pharmaceuticals ($WPI) said a U.S. District Court invalidated a patent on Sanctura XR, an overactive bladder treatment, a drug it's hoping to knock off. Report

> Adding Erbitux to standard chemotherapy didn't make a significant difference in survival for colon cancer patients who'd had surgery, a study found. Item

Biotech News

@FierceBiotech: AstraZeneca scouts new drug deals to silence a chorus of critics. Story | Follow @FierceBiotech

@JohnCFierce: Burrill counted up all the early-stage venture funds coming together and ID'd $2.6B over just a few weeks. Serious $$. Release | Follow @JohnCFierce

@RyanMFierce: In case you missed, device that can detect neural activity called iBrain in the spotlight, famous ALS patient outfitted: Article | Follow @RyanMFierce

> OvaScience grabs $37M B round for fertility treatments. News

> Billions in new venture cash targeted at early-stage biotech efforts. Article

Medical Devices News

@FierceMedDev: St Jude To Stop Selling Another Version Of Defibrillator Wires | Fox BusinessNews | Follow @FierceMedDev

> Study: Metal hips don't heighten cancer risks. Item

> Imaging boosts breast cancer finds. Story

> Bio-Rad founder dies; stock soars on sale spec. More

Drug Delivery News

> After Astellas fallout, Zogenix strikes deal with Battelle to market DosePro. Article

> Is ImmunoGen overvalued? Item

> INSYS and Aptar launch under-the-tongue delivery for cancer pain drug. More

> Novartis touts positive results for COPD inhalant. Report

Biomarkers News

> Biomarkers could tag breast cancer recurrence earlier. News

> DNA biomarker pinpoints hep B liver cancers. Story

> Survivin could be key to survival in pancreatic cancer. Article

> Allergy biomarkers could track treatment response. Item

And Finally... Scientists are questioning a flurry of media coverage about the utility of genetic sequencing. Report